Should Patients at High Risk of Peritoneal Dissemination from Gastric and Colon cancers Undergo HIPEC as an Adjuvant Therapy?

Apr 20, 2021

In this episode, Edward Levine, MD Chair of the SSO Peritoneal Surface Malignancy DSWG, is joined by Brian Badgwell, MD of MD Anderson Cancer Center and Pieter Tanis, MD, PhD of the University of Amsterdam.  They discuss whether patients at high risk of peritoneal dissemination from gastric and colon cancers should undergo HIPEC as an adjuvant therapy.